检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]湖北省中医院,武汉430060
出 处:《中国中医骨伤科杂志》2011年第6期25-27,共3页Chinese Journal of Traditional Medical Traumatology & Orthopedics
摘 要:目的:观察跌打七厘片治疗急性软组织损伤气滞血瘀证的临床疗效。方法:将456例病人随机分为两组。治疗组342例服用跌打七厘片,对照组114服用复方三七胶囊,疗程均为10d。在治疗前后观察疼痛、肿胀、瘀斑、压痛、功能障碍的积分变化情况;同时进行肝肾功能,血、尿、粪常规及血汞、尿汞的检验评价药物使用安全性。结果:治疗组痊愈率72.3%,显效率16.4%,对照组痊愈率60.7%、显效率19.6%,2组比较差异有统计学意义(P<0.05);治疗组和对照组在疼痛、瘀斑、压痛、功能障碍、口干、失眠方面比较差异有统计意义(P<0.05);在肿胀、便秘方面治疗组与对照组比较差异无统计意义(P>0.05)。结论:跌打七厘片治疗急性软组织损伤安全、有效,具有明显的活血、散瘀、止痛作用。Objective:To observe the clinical effect of Diedaqili tablets for treatment to acute traumatic soft tissue injury with blood stasis Syndrome.Methods:All of 456 patients were randomly divided into two groups.342 patients took Diedaqili tablets in treatment group;342 patients took Sanqi compound tablets in the control group,a course of 10 days in both of the two group.Pain,swelling,ecchymosis,tenderness,score changes of dysfunction were observed before and after treatment;The liver and kidney function,blood,urine,stool,blood mercury and urine mercury were tested in order to assess the safety of Diedaqili tablets.Results:The cure rate and markedly effective rate was 72.3%,16.4% separately in treatment group;the cure rate and markedly effective rate was 60.7%,19.6% separately in control group;There was significant statistically difference(P0.05);There was significant statistically difference in pain,ecchymosis,tenderness,dysfunction,dry mouth,insomnia,between treatment group and control group.There was no significant statistically difference(P0.05) in swelling,constipation between treatment group and control group.Conclusion:Diedaqili tablets are safe and effective in the treatment to acute traumatic soft tissue injury,and it has significant blood circulation,stasis and analgesic effects.
分 类 号:R274.3[医药卫生—中医骨伤科学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.40